Sepracor's 1st-qtr revenues jump 3%

US drugmaker Sepracor's first-quarter 2009 revenues jumped 3% year-on-year to $330.2 million, as GAAP net income grew to $35.2 million  from $7.1 million. Non-GAAP profit totaled $96.8 million versus $62.5  million.

Turnover of sleep disorder drug Lunesta (eszopiclone) reached $140.4  million, up 4%, while Xopenex (levalbuterol HCl) inhalation solution  fell 16% to $118.0 million. The short-acting beta-agonist is indicated  for the treatment or prevention of bronchospasm in patients with asthma  and chronic obstructive pulmonary disease.

Sales of Xopenex HFA (levalbuterol tartrate HFA) aerosol, a  hydrofluoroalkane metered-dose inhaler for the treatment or prevention  of bronchospasm, earned $20.1 million, largely flat on the year before.  Brovana (arformoterol tartrate) inhalation solution, a long-acting,  twice-daily maintenance treatment for COPD bronchoconstriction, soared  87% to $18.5 million, while hay fever nasal spray Omnaris (ciclesonide)  generated $5.9 million after being launched last April.